Journal of Crohns & Colitis

Article	Citations
P470 Ustekinumab Trough Levels are not Associated with Clinical Response in Inflammatory Bowel Disease Patients	560
DOP59 Evaluation of the efficacy of tofacitinib as maintenance therapy in patients with Ulcerative Colitis stratified by OCTAVE Sustain baseline endoscopic subscore	150
P572 Therapy optimisation and intravenous ferric carboxymaltose in active or inactive IBD with iron deficiency: it’s time to make iron deficiency part of tight monitoring to reach T2T? – preliminary r	139
P554 Does vitamin D level correlates with disease activity in inflammatory bowel disease patients?	134
P588 Steroid sparing effect of adalimumab in cortisone–depended ulcerative colitis patients	113
P678 Definition of a microbial signature as a predictor of post-surgical recurrence in patients with Crohn’s disease	101
P664 Bidirectional association between inflammatory bowel disease and psoriasis in a pediatric population: A nationwide insurance claim data analysis in South Korea	91
P622 Comparison of midterm outcomes in Pediatric Crohn’s Disease patients treated with either Exclusive Enteral Nutrition or Corticosteroids around disease diagnosis– a population based study	82
P135 Proximal Extension of lower rectal Ulcerative Proctitis	77
P467 Therapeutic drug monitoring of biologics in Inflammatory Bowel Disease: Nordic survey on implementation and barriers in clinical practice	73
P574 Exploring treatment of Crohn’s disease and ulcerative colitis in the Middle East and Northern Africa: An analysis of the HARIR observational cohort study	73
DOP87 Association of histologic measurement with endoscopic outcomes after one year of treatment with mirikizumab in patients with moderate to severe Crohn’s Disease	71
DOP35 Ambulatory care management of 70 patients with Acute Severe Ulcerative Colitis in comparison to 700 inpatients: Insights from a multicentre UK cohort study	67
P350 SAFIIR: Study of Anemia Following Intravenous Iron Repletion	60
P132 An audit of quality of histopathology reporting of colorectal mucosal biopsies for the diagnosis and assessment of Inflammatory Bowel Disease	59
P404 Healthcare utilization and expenditures for patients with Ulcerative Colitis on advanced therapies in Germany	58
P175 Low relapse rates after biologic therapy discontinuation in a large real life cohort of IBD patients with initial severe disease: do biologics alter the natural history of disease?	55
P659 Colonoscopic screening of symptomatic patients suggests an emerging inflammatory bowel disease (IBD) in urban and rural south India	53
P341 Fracture risk in middle-age and older patients with inflammatory bowel disease: A Korean nationwide population-based cohort study	51
P518 Compliance with Faecal calprotectin home testing as standard during COVID-19 pandemic compared to laboratory based testing pre-COVID	50
P708 Ileal involvement defined by Montreal classification in Crohn’s disease is associated with a distinct microbial composition in ileal and colonic mucosa	48
P719 Identification of differentially expressed genes between AIEC and non-AIEC clinical isolates during in vitro cell infection	48
P452 Oral ciclosporin is a convenient, effective and safe rescue therapy in steroid refractory Acute Severe Ulcerative Colitis: A single tertiary centre experience	44
P394 Serological biomarkers of type III and IV collagen remodeling predict and monitor infliximab treatment response in patients with Inflammatory Bowel Disease	44
P697 Examining the regulatory role of epigenetic and transcriptomic alterations in anti-TNFα treatment response and disease progression in patients with Ulcerative Colitis	43

P513 Treatment persistence in bio-naive patients with long-standing Crohn’s disease treated with first-line biologics: real-life data from a Croatian tertiary center	42
P466 Acute Severe Ulcerative Colitis in the modern era: biologic therapy-exposed patients and salvage therapy with intensified infliximab	42
OP07 Artificial intelligence surpasses gastrointestinal experts in the classification of endoscopic severity among Ulcerative Colitis	42
P623 The effectiveness and tolerability of Crohn’s disease exclusion diet in adult Crohn’s disease patients: a retrospective study	41
Inequitable Access to IBD Therapies Extends Beyond Developing Nations	41
P014 Impact of experimental ileitis and Toll-Like Receptor 4 signaling on enteric inhibitory neurotransmission	40
P354 Early treatment versus active surveillance after ileocolic resection in Crohn’s disease: a retrospective cohort study	39
P247 Comparison of discontinuation/switching between infliximab biosimilar and originator among Inflammatory Bowel Disease patients: a real-world analysis of two Canadian cohorts	38
P666 Trend of Lower gastrointestinal Endoscopy in Patients with Inflammatory Bowel Diseases: A Nationwide Population-Based Study in South Korea	36
P172 Clinical characteristics of newly diagnosed adult patients with Crohn’s disease in Japan: Interim analysis of Inception cohort registry study of patients with Crohn’s disease (iCREST-CD)	36
DOP19 Urinary metabolome in newly diagnosed treatment-naïve Crohn’s Disease patients: Results from the IBDomics study	36
P096 Which patients with known Crohn’s disease after an ileo-colonoscopy will benefit most from small bowel capsule endoscopy?	36
P223 Degree of Histological Activity is not Associated with Vedolizumab Therapy Outcome in Ulcerative Colitis	35
P664 Adherence to mesalazine and identification of patients with ulcerative colitis in healthcare administrative databases of Tuscany (Italy)	35
DOP82 Corticosteroid-free remission of Ulcerative Colitis with filgotinib maintenance therapy: Post hoc analysis of the phase 2b/3 SELECTION study	34
P309 Withdrawal of thiopurines in Inflammatory Bowel Disease patients in stable remission: a prospective, multicentre cohort study	34
P604 Evaluation of management heterogeneity and complications of Crohn’s disease in Catalonia. A population quality care study	33
P269 Spaciotemporal machine learning analysis of complete small bowel capsule endoscopy videos for prediction of outcomes in Crohn’s disease	32
P169 Vitamin D levels are inversely associated with inflammation in pediatric InflammatoryBowel Disease patients	32
P184 Relationship Between Patient Sex and Serum Tumor Necrosis Factor Antagonist Drug and Anti-Drug Antibody Concentrations in Inflammatory Bowel Disease; A Nationwide Cohort Study	32
P595 Finding predictors of azathioprine-induced pancreatitis in patients with inflammatory bowel disease	30
P165 Characterization and risk of sarcopenia in patients with Ulcerative Colitis, compared with older and younger adults. Cross-sectional study	30
P481 Effectiveness and safety profile of biological therapy in inflammatory bowel disease: real life data from an active pharmacovigilance project	30
N12 Systematic Review: The role of psychological stress in Inflammatory Bowel Disease	29
P375 Faecal calprotectin variation after induction therapy with infliximab to predict clinical, endoscopic and ultrasonographic remission in Crohn’s disease patients	29
P207 COVID-19: a prevalence rate two times lower than that of the general population in French patients with Inflammatory Bowel Disease treated with intravenous biologic agents	29
P200 Celiac disease (CD) and CHRONIC INFLAMMATORY BOWEL DISEASE (IBD) association	29
P645 Ileocecal resection in paediatric Crohn’s disease based on the Hungarian Paediatric IBD Registry	29
P032 Host transcriptome signatures in human fecal-washes predict histological remission in IBD patients	29
P672 Biologic therapy for Inflammatory Bowel Disease in Poland in 2020: nationwide data	29
P036 MicroRNA composition of colon crypt-top and crypt-bottom epithelial cells in Ulcerative Colitis	29
P438 The Efficacy and Safety of ustekinumab Therapy in refractory Inflammatory Bowel Disease (IBD) patients with co-morbidities and old age	29
Anti-TNF nonresponse in ulcerative colitis: correcting for mucosal drug exposure reveals distinct cytokine profiles	28
P469 Infliximab for induction of medically-induced remission in Crohn’s disease: a Cochrane systematic review	28
Radiation exposure in patients with inflammatory bowel disease	28
A new protocolized treatment strategy optimizing medical and surgical care leads to improved healing of Crohn’s perianal fistulas	28
P548 External validation and consistency in time of patient segmentation based on disease acceptance and perceived control in Inflammatory Bowel Disease	27
P027 Effects of anti-TNF and anti-α4β7 drugs on circulating monocytes migratory capacity in inflammatory bowel disease	27
P201 Crohn’s Disease of the terminal ileum associated with ileo-sigmoid fistula: risk factors for ileostomy formation and postoperative complications during the years of biologics	27
N02 The importance of the multidisciplinary team (MDT) and its impact on quality of life and medication adherence in patients with Inflammatory Bowel Disease	27
P674 Predictors of response to biologics in Crohn’s Diseases: A population-based study from the epi-IIRN	27
P051 Macrophages as a source of Notch Ligands in Crohn’s disease: implications in fibrosis	27
DOP61 Development and validation of novel models in prediction of intravenous corticosteroids resistance in patients with Acute Severe Ulcerative Colitis	27
DOP44 Long term outcomes of patients with untreated IBD - A population-based analysis from the epi-IIRN	27
P025 A review of the newly implemented Inflammatory Bowel Disease dietetic service	26
P631 Impact of Covid-19 pandemic on initiation of immunosuppressive treatment in immune-mediated diseases. -A nationwide, retrospective study	26
P162 Microscopic inflammation in limited Ulcerative Colitis at diagnosis: can a single histological feature predict prognosis?	26
P360 Aggressive Inflammatory Bowel Disease is associated to Hermansky-Pudlak Syndrome: Characterization of a Puerto Rican Cohort	26
P462 Impact of teduglutide, a GLP-2 agonist, on inflammatory bowel disease-associated short bowel syndrome: a tertiary single-center study	26
P264 Prevalence and predictors of stoma formation and restoration of intestinal continuity in patients with Crohn’s disease in a tertiary referral hospital: A retrospective explorative study	26

P428 Early and Late Fecal Calprotectin Remission - Analysis of a proactive Therapeutic Drug Monitoring Treatment Protocol	26
P363 Are clinical decision support tools for vedolizumab and ustekinumab in biologic naïve patients with Crohn’s disease drug-specific?	25
P425 Rates of tuberculosis infection in Crohn’s Disease patients before and during anti-tumor necrosis factor therapy	25
P414 Stoma in patiens with IBD: friend or foe? -\tEffect of stoma on course of disease, psychological well-being and working capacity	25
P130 Adhesions are not always the enemy: pouch volvulus	24
DOP16 The ratio of submucosa thickness to the total bowel wall thickness can be a sonographic parameter to estimate endoscopic remission in Ulcerative Colitis	24
P763 Rare and severe adverse events in pediatric inflammatory bowel disease: identification of safety signals through the international prospective PIBD-SETQuality Safety Registry	24
P525 Patients’ Perception of Risks of biologic therapy During Covid-19 Pandemic in Israel Orly Lior, Ilia Sergeev, Nahum Ruhimovich, Michal Openheim, Fabiana Benjaminov, Dan Feldman, Yehuda Ringel, Ti	24
P620 A cost-effective Inflammatory Bowel Disease flare management pathway utilising rapid access intestinal ultrasound and nurse-led triage to achieve hospital avoidance with increased patient satisfa	24
P463 COVID-19 vaccination willingness and hesitancy in patients with Inflammatory Bowel Diseases (IBD): analysis of determinants in a national survey of the Italian IBD patients’ association (AMICI On	24
P447 Anti-αvβ6 integrin antibody as a novel serum biomarker for diagnosis of ulcerative colitis; a nation-wide multicenter validation study in Japan	23
P156 Submucosa hypertrophy of active UC patients suggests transmural involvement in UC-associated inflammation	23
P662 Pre-treatment vitamin D concentrations do not predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn’s disease	23
P679 Is the burden of obesity in IBD bigger than just weight?	23
OP15 Efficacy of ustekinumab for Ulcerative Colitis through 4 years: Final clinical and endoscopy outcomes from the UNIFI long-term extension	23
P091 Single-cell metabolic phenotyping of monocytes and macrophages in Crohn’s disease	23
P912 Increased Primary Bile Acids with Ileocolonic Resection Impact Ileal Inflammation and Gut Microbiota in Inflammatory Bowel Disease	23
P755 Impaired antibody seroconversion after COVID-19 vaccination and negative impact of immunosuppressive treatment in Inflammatory Bowel Disease. Results from a multicentre, prospective study of GETE	22
P472 A Real World Practice of Intestinal Ultrasound in the Monitoring of Disease Activity in Ulcerative Colitis	22
P680 Comparative risk of serious infection with vedolizumab vs anti-TNF in Inflammatory Bowel Disease: Results from nationwide Swedish registers	22
P502 Multimodal profiling of peripheral blood identifies proliferating circulating effector CD4 T cells as predictors for response to integrin alpha4 beta7-blocking therapy in patients with Inflammato	22
Letter to the Editor	22
P840 Structural evaluation of Inflammatory Bowel Disease Comprehensive Care Units in Brazil	22
P335 Impact of cancer therapy on the course of Inflammatory Bowel Disease (ONCOEII study of GETECCU)	21
Bacteroides fragilis Toxin Suppresses METTL3-Mediated m6A Modification in Macrophage to Promote Inflammatory Bowel Disease	21
P290 Development of an artificial intelligence model using stool pictures for predicting endoscopic mucosal inflammation in patients with Ulcerative Colitis; KASID multicenter study	21
A pro-inflammatory diet is associated with growth and virulence of Escherichia coli in pediatric Crohn’s disease	21
Prevalence, incidence, and mortality of inflammatory bowel disease in the Netherlands: development and external validation of machine learning models	21
P212 The Impact of Crohn’s Disease in Patients with Colorectal Cancer: A Danish Nationwide Cohort Study, 2009-2019	21
P236 Endoscopic Recurrence or Anastomotic Wound Healing Phenomenon after Ileocolic Resection for Crohn’s Disease: The Challenges of Accurate Endoscopic Scoring	21
Disease-modifying anti-inflammatory drugs (DMAIDs): shaping the future of inflammatory bowel disease	21
P447 Positioning of ustekinumab affects its effectiveness, drug persistence and serum exposure in Crohn’s disease	20
P209 Prevalence and risk factors for fatigue in chronic inflammatory bowel disease	20
P487 The feasibility of a digital platform for improving disease management among patients with Ulcerative Colitis	20
P416 Addition of oral antibiotics to mechanical bowel preparation significantly improves anastomotic healing after ileocolic resection for Crohn’s disease	20
P490 Patients with inflammatory bowel disease should be vaccinated against pneumococcus and influenza despite immunosuppressive therapy	20
P570 Prevalence and risk factors for intestinal resection in patients with Crohn’s disease in a Greek referral center	20
P241	20
P286 Ustekinumab for Crohn’s Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study	20
P368 Safety issues of azathioprine in patients with inflammatory bowel disease: clinical experience from a referral center	20
P007 ORMDL proteins shape homeostasis in the intestinal epithelium by regulating endoplasmic reticulum architecture and autophagy	20
P448 Safety of anti-TNF introduction following tuberculosis treatment in Inflammatory Bowel Disease patients in an endemic area	20
P419 Psychological acceptability of surgery in patients with ulcerative colitis after total colectomy	19
P156 Translation into Spanish, adaptation and validation of the “IBD- control”, a short validated English PRO (patients reported outcomes) questionnaire: the EII-Control	19
P453 The use of immunosuppresants is associated with high treatment persistence rates for infliximab and adalimumab as first or second line anti-TNF therapy in patients with inflammatory bowel disease	19
P578 Adriatic-Balkan regional survey on COVID-19 in Inflammatory Bowel Disease patients	18
P169 Delayed diagnosis of inflammatory bowel disease in women: Characterization and use of health resources	18
P410 Safety of biological drugs for inflammatory bowel disease in elderly patients	18
P1067 Comparison of AZA-Related Pancreatitis and AZA-Related GI Intolerance Based on Demographic Factors, Clinical Variables and HLA DQA1/DRB1 Alleles	18
P588 T cell response to SARS-CoV-2 mRNA vaccines by an interferon-gamma release immunoassay in patients with Inflammatory Bowel disease receiving anti-TNF and thiopurine treatment	18
P581 Pre-operative prolonged antibiotic treatment in ileocecal Crohn’s disease: single center non-randomized prospective study	18
Disruption of Epithelial Barrier Integrity via Altered GILZ/c-Rel/RACK1 Signaling in Inflammatory Bowel Disease	18
Tobacco Smoke Exposure in Early Childhood and Later Risk of Inflammatory Bowel Disease: A Scandinavian Birth Cohort Study	18
P528 Feasibility, satisfaction and machine learning analysis of factors influencing IBD patients’ trust in the mobile application Care4today IBD	18
P475 Real world data on treatment success and drug persistence in anti-TNF therapy for ulcerative colitis	17
P234 Association between anti-TNFα drug levels and drug-induced lupus in patients with Inflammatory Bowel Disease	17
P577 Withdrawal of thiopurines in patients with Ulcerative Colitis in remission	17
P713 Gut microbiota alterations after bowel preparation amongst inflammatory bowel disease patients	17
P199 Analysis of clinical features of asymptomatic perianal fistulizing Crohn’s disease	17
P333 Precise and unbiased infliximab dosing in patients with inflammatory bowel diseases using a multi-model averaging approach	17
P155 Bowel preparation is valued more than colorectal cancer risk and interval by patients in colitis-associated colorectal cancer surveillance: a discrete choice experiment	17
P022 Pathologic involvement of the farnesoid X receptor/fibroblast growth factor 19 axis to the Crohn’s disease early postsurgical recurrence	17
P523 Survey to identify patient characteristics, treatment preferences and impact of inflammatory bowel disease (IBD) on quality of life across 7 countries in Europe	17
P147 Do IBD Patient Treatment Outcomes Expectations Differ by Ethnicity and Gender?	17
P105 Coping in Inflammatory Bowel Disease: insights from the Crohn’s and Colitis UK national survey	17
P215 Blood-based prognostic biomarkers in Crohn’s patients treated with biologics: a new promising tool to predict endoscopic outcomes	17
P489 Rescue treatment with original versus biosimilar infliximab in biologic-naïve patients with moderate-severe Ulcerative Colitis and corticosteroid failure	17
OP18 Treatment of perianal fistulas in Crohn’s Disease: Surgical closure after anti-TNF induction treatment versus anti-TNF without surgery (PISA II) - A patient preference RCT	16
P144 Changes of fecal metabolic and lipidomic features by anti-tumor necrosis factor treatment and prediction of clinical remission in patients with ulcerative colitis	16
P130 Comparison of the clinical course of Ulcerative Colitis according to the presence or absence of clinical symptoms at the time of diagnosis	16
P492 A comparison of treatment effects for clinical, endoscopic and histological remission in ulcerative colitis clinical trials	16
DOP39 Utilization and sustainability of biologics in UC - A nationwide study from the epi-IIRN	16
P439 Effectiveness of Ustekinumab on Crohn’s disease associated spondyloartropathy: real-world data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)	16
OP22 Antibody decay, T cell immunity and breakthrough infections following SARS-CoV-2 vaccination in infliximab- and vedolizumab-treated patients	16
DOP36 Non-invasive assessment of postoperative disease recurrence in Crohn’s Disease: A multicenter, prospective cohort study	16
P568 Effectiveness of ustekinumab after vedolizumab failure in patients with anti-TNF-refractory Crohn’s disease	16
P438 Maladaptive decision-making is associated with psychological morbidity in people with Inflammatory Bowel Disease	16
P112 Impact of the SARS-COV2 pandemic on patients with inflammatory bowel disease - Preliminary results of a prospective, single-center study	16
P714 Comparison of intestinal microbiota profiles of faecal samples, rectal swabs and mucosal biopsies in patients with Inflammatory Bowel Disease. A multicentre, observational study	16
P520 ‘Eetscore’ in patients with Inflammatory Bowel Disease: an online tool to assess diet quality and provide personalised dietary advice	16

P468 Evaluation of work productivity and activity impairment in moderate-to-severe ulcerative colitis participants treated with ozanimod in the phase 3 True North study	16
P381 Fatigue is an independent disease manifestation largely independent of chronicity, comorbidity and disease activity in patients with Inflammatory Bowel Disease	16
P253 A qualitative study exploring meaningful improvement in bowel urgency among adults with moderate to severe Ulcerative Colitis	16
DOP05 Morbid obesity, a new susceptibility factor for developing Inflammatory Bowel Disease. Results of a population-based study	16
P171 PSC/IBD and IBD have similar type and location of colonic lesions, but Dye ChromoEndoscopy (DCE) increases detection rate compared to White Light Endoscopy (WLE)	15
DOP55 Long-term outcomes after histologic-endoscopic mucosal healing: Results from the UNIFI study in Ulcerative Colitis	15
OP19 Classifying perianal fistulising Crohn’s Disease: An expert-consensus to guide decision-making in daily practice and clinical trials	15
P265 Open approach for ileocolic resection in Crohn’s disease in the era of minimally invasive surgery: indications and perioperative outcomes in a referral centre	15
P507 Vulvar Crohn’s disease: A challenging diagnosis	15
P686 Outcomes of COVID-19 among patients with inflammatory bowel diseases and the influence of IBD-related medications– A Danish prospective population-based cohort study	15
P521 Correlation between physician disease assessment in Ulcerative Colitis and burden of disease: ICONIC 2-year data of 120 patients in Turkey	15
P926 Blautia Obeum Aggravates Colitis in a Murine Model	15
P406 Disease clearance in patients with ulcerative colitis treated with aminosalicylates	15
P442 Serum vedolizumab trough levels are associated with remission rate but not with extra-intestinal manifestations in IBD patients	15
Erratum to: Post-inflammatory Polyp Burden as a Prognostic Marker of Disease-outcome in Patients with Inflammatory Bowel Disease	15
P634 Trajectories of oral budesonide use in Crohn’s disease cohort of Tuscan patients	15
P120 Developing “My quality of life” programme based on ICHOM Standard Set for IBD: 1-year results	15
P325 Performance of new MRI scores: the modified Van Assche Index and the MAGNIFI-CD in the evaluation of the response to anti-TNFα in anoperineal fistulas in Crohn’s disease	15
DOP50 Recommencement of Inflammatory Bowel Disease medications following colectomy for Ulcerative Colitis	15
P474 Postoperative infectious complications in patients with Inflammatory Bowel Disease: experience of a tertiary center	15
DOP35 Increasing incidence of pouchitis among patients undergoing ileal pouch-anal anastomosis between 1996 and 2018: A population-based Danish cohort study	15
P582 Association between serum ustekinumab concentrations and endoscopic disease activity in Crohn’s disease	15
P429 Continued postoperative use of biologics for the prevention of recurrence of Crohn’s disease	15
P257 The clinical decision support tool has low performance in predicting outcome to ustekinumab in Crohn’s disease	14
Improvement in serum eosinophilia is observed in clinical responders to ustekinumab but not adalimumab in inflammatory bowel disease	14
P662 A retrospective claims analysis on the prevalence and incidence of ulcerative colitis in Germany and the frequency of advanced therapy use	14
P346 Assessing Brain Morphology in Functional Gastrointestinal and Inflammatory Bowel Disorders Using Functional Magnetic Resonance Imaging (fMRI)	14
P301 Relapse rates after withdrawal of thiopurines in patients with Inflammatory Bowel Disease	14
P426 Health-Related Quality of Life and Work Productivity in patients with moderate-to-severe Inflammatory Bowel Disease in Argentina: Data from the RISE AR study	14
Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies	14
P551 Platelet-to-lymphocyte ratio index for non-invasive assessment of endoscopic activity in small bowel Crohn’s disease: application and prospective validation.	14
N18 Exploring the experiences of UK-dwelling Bangladeshi native language-speaking patients with Inflammatory Bowel Disease: preliminary findings from a qualitative study	14
P699 Machine Learning-based Prediction for Early Progression in Korean Crohn’s disease: Results from the IMPACT Study	14
P059 Diet controls segmented filamentous bacteria in driving Crohn’s disease-like inflammation in TNFdeltaARE mice	14
P549 Oxidative stress and antioxidant capacity biomarkers in adults and children with IBD: current update from OxIBDiet trial	14
P060 Restoration of occludin and claudin-1 expression in patients with Crohn’s disease receiving anti-TNF treatment.	14
OP34 Risk of Disease Recurrence and Re-resections in Crohn's Disease Patients Undergoing Primary Bowel Resection: A Population-Based Study	14
P089 Colonic explant lactate concentration and inflammatory protein secretion in ulcerative colitis	14
P387 Rapid Implementation of an Evidence-Based, Virtual COVID-19 Vaccine Education Clinic at the Nova Scotia Collaborative Inflammatory Bowel Disease Clinic (NSCIBD) Program	14
P616 Safety of COVID-19 vaccines in patients with IBD	13
P687 Prevalence of iron deficiency and anaemia in the outpatient Inflammatory Bowel Disease population: a Dutch national cross-sectional study	13
P202 De novo Inflamatory Bowel Disease after solid organ transplantation	13
P244 Clinician preferences in treating steroid resistant ulcerative colitis: a discrete-choice experiment (DCE) survey	13
N16 ‘Same storm, different boat’… Exploring the impact of the COVID-19 pandemic on patients with Inflammatory Bowel Disease, with or without shielding: a qualitative study	13
P101 Isosteviol Attenuates Dextran Sulfate Sodium-Induced Colitis by Maintaining the Intestinal Barrier Through PDK1/AKT/NF-κB Signaling	13
P334 Tofacitinib for the treatment of Ulcerative Colitis: Analysis of malignancy rates from the Ulcerative Colitis clinical programme	13
P090 Unraveling the rewiring of cytokine signalling in Inflammatory Bowel Disease using a novel network biology approach	13
DOP88 Long-term real-world data of ustekinumab in Crohn’s Disease – the Stockholm ustekinumab study – STOCUSTE	13
P057 Mucosal microbiota adapts to ATF6-induced alterations in host lipid metabolism with prognostic value in colorectal cancer	13
P483 Patient-reported quality of life, anxiety, and depression associated with switching originator infliximab to biosimilar	13
P193 Assessement of cumulative bowel damage using Lemann index and MaRIA score in surgically naive patients with Crohn’s disease	13
P672 A tertiary multicenter cohort of patients with chronic intestinal pseudo-obstruction and Crohn’s disease: a rare association with a high prevalence of monogenic disorders	13
P208 Differentiating intestinal tuberculosis from Crohn’s Disease: External validation of a new nomogram	13
OP14 Interpreting genome-wide association studies of Inflammatory Bowel Disease through the lens of single-cell sequencing	13
P619 Patterns of Anti-TNF Prescribing & Therapy Outcome in a Large Multicentre Cohort of Inflammatory Bowel Disease Patients	13
P367 Significant impact on health care utilization upon implementation of an electronic IBD care management program.	12
P054 Secreted inflammatory protein profiles following treatment of ex-vivo human inflammatory bowel disease explants with licenced biologic therapies	12
P220 Patient’s disease perception and health-related quality of life with IBD: Results from a Spanish cohort with 15 years of follow up	12
P751 Crohn’s Disease Exclusion Diet: A single centre real-life experience	12
P422 Transition from intravenous to subcutaneous infliximab and vedolizumab: adherence, satisfaction and safety profile in a cohort of patients with Inflammatory Bowel Disease	12
P308 A new endoscopic scoring system corresponding to histological healing using linked color imaging in ulcerative colitis: SOUL study	12
P442 Endoscopic resection of visible precancerous lesions in patients with colonic Inflammatory Bowel Disease	12
P043 Succinate receptor (SUCNR1) mediates leukocyte-endothelial cell interactions induced by TNFa	12
P181 infliximab exposure during induction associate with time to remission and disease control of inflammatory bowel disease	12
P316 Inflammatory Bowel Disease and malignancy: What are the predictors of malignancy in Inflammatory Bowel Disease?	12
P067 Fractal analysis of extracellular matrix as a new histological method for observer-independent quantification of intestinal fibrosis in Crohn’s Disease	12
P232 Serum neutrophil gelatinase associated lipocalin (NGAL) as a marker of activity of Inflammatory Bowel Disease	12
P364 Presence of malnutrition adversely affects short-term clinical outcomes in a sample of patients with Crohn's disease (CD)	12
P177 C-reactive protein/albumin ratio: a novel biomarker for monitoring of the disease activity in Ulcerative Colitis patients	12
P622 Change in Dietary Inflammatory Index Score in patients with Crohn’s disease and healthy volunteers following the Groningen Anti Inflammatory Diet (GrAID)	12
DOP25 Contraceptive method use according to Inflammatory Bowel Disease status among young women in the United States	12
P580 Upadacitinib is effective and safe for Ulcerative Colitis: prospective real-world experience	12
P909 Microbiome dynamics leading up to and during pregnancy in a matched IBD-control cohort	11
P501 Safety of peri-operative biologics in patients with IBD undergoing resective bowel surgery: experiences of a single center cohort	11
P127 Inflammatory Bowel Disease-associated colorectal cancers: retrospective cohort study from a tertiary centre surveillance programme over 10 years	11
P470 Evolution of asymptomatic unresected lesions in patients operated for multifocal Crohn’s disease.	11
P465 Health-related quality of life from the Inflammatory Bowel Disease Questionnaire in patients with ulcerative colitis treated with etrasimod in the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials	11
P898 Uncovering of tissue-associated risk factors that lead to different genetic risk profiles across Inflammatory Bowel Disease patients	11
P508 Sarcopenia is associated with increased rates of infectious post-operative complications in Crohn’s disease patients	11
P477 Patient satisfaction and cost saving analysis of telemedicine in patients with inflammatory bowel disease.	11
P403 Therapeutic compliance in patients with chronic inflammatory bowel disease.	11
P430 Mesalazine dose modification based on fecal calprotectin levels in ulcerative colitis patients in clinical remission	11
P042 Distinct gene expression profile associated to inflammation and neoplastic progression in longstanding ulcerative colitis	11
P418 Dose escalation of oral 5-aminosalicylic acid for ulcerative colitis with Mayo endoscopic subscore of one improves long-term prognosis: a one-year multicentre, open-label, randomized controlled t	11
P113 Protein fingerprint biomarkers of collagen remodeling can evaluate fibrogenesis in an in vitro colonic scar-in-a-jar model	11
P222 Chronic pain is common in Paediatric Inflammatory Bowel Disease and impacts quality of life	11
P494 Impact of early optimization of ustekinumab on mid-term targets in severe Crohn’s disease: THE MUST study	11
P324 Long-term impact of the COVID-19 pandemic on Inflammatory Bowel Disease healthcare utilization: A two-year nationwide update	11
P842 SARS-CoV-2 antibody titers analysis in immune mediated inflammatory disease patients after COVID-19 vaccination: a monocentric retrospective study	10
P852 predictors of complicated disease course in UC in an administrative database: a nationwide study from the epi-IIRN	10
P825 The course of inflammatory bowel disease in setting of liver transplantation	10
P850 Co-medication before and after onset of inflammatory bowel disease in adults or elderly	10
P843 Mucinous and signet-ring colonic adenocarcinoma in Inflammatory Bowel Disease	10
P823 Biologic Penetration, hospitalization rates and need for major abdominal surgery in inflammatory bowel diseases: a comparative observational study between pediatric and adult patients	10
N05 Highlighting the critical contributions of Inflammatory Bowel Disease nurses in Canada: Perspectives from nurses, gastroenterologists, individuals living with IBD, and caregivers.	10